Company
NASDAQ:CNTX
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company committed to advancing medicines for solid tumors, with a primary focus on female cancers. The Company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development. Additionally, the company is advancing onapristone extended release (ONA-XR), a novel, first-in-class, potent, and selective progesterone receptor antagonist, currently in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancers. Context is headquartered in Philadelphia.
32 stories · page 2 of 2
The women’s oncology company said the lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrated strong efficacy across multiple PR+ solid tumor models
The women's oncology company expects its cash balance will be sufficient to fund operations into 2024
Five abstracts have been selected for poster or symposium presentations at the event in New Orleans, Louisiana
“With multiple data readouts expected in 2022, we foresee several inflection points in the coming months,” Edison analysts said
The clinical-stage biopharmaceutical company focused on bettering the lives of women living with cancer, is developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancer
Christopher Beck will take on the role of senior vice president of operations and Mark Fletcher will be the firm’s new vice president of R&D
“This readout is the first for the novel PR antagonist, and the results are encouraging early evidence of the potential of ONA-XR to offer a new therapeutic option for hormone-dependent cancers,” said Martin Lehr, CEO of Context Therapeutic
The company issued 5 million of its common shares, at a price of $6.25 each, plus 5 million common share purchase warrants with a five-and-one-half year term and an exercise price of $6.25 per share
Archive
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
The women’s oncology company debuted on Nasdaq and entered into a $31.25 million private placement agreement that extends its cash runway into 2024
The Massachusetts-based biopharma is led by former Pfizer CEO Jeffrey B. Kindler
